MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Persistence Market Research (P) Ltd
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR - Topical drug formulation are made up in a vehicle or base which is made specific to the site of the body or type of skin - PersistenceMarketResearch.com
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR

 

NewswireToday - /newswire/ - New York, NY, United States, 2017/06/30 - Topical drug formulation are made up in a vehicle or base which is made specific to the site of the body or type of skin - PersistenceMarketResearch.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Topical drugs are used for the application where body surfaces such as the skin or mucous membranes to treat ailments. OTC Topical drugs are epicutaneous medication that are applied in the skin directly. The large range of classes included in the topical drugs are creams, foams, gels, lotions and ointments. The advantage of reduced side effects to the other organ. Disadvantage of topical formulation is that it is time consuming, complicated and uncomfortable sometimes. Topical drug formulation are made up in a vehicle or base which is made specific to the site of the body or type of skin. The amount of ingredients observed in the skin totally depends upon type of skin. The different type of formulation of OTC topical drugs includes lotions, creams, ointment, gel, paste etc. Lotions that are usually thicker than a solution and contains oil and water or alcohol. Cream which is thicker than a lotion and usually maintains a shape of 50/50 emulsion of oil and water, it often requires preservatives and maintains the moisture. Ointment is semi-solid, water-free or nearly 80% oil. No need for preservative son contact allergy is rare in case of ointments. Ointments usually contains wool fat, emulsifying wax, macrogols, vegetable oils, beeswax, paraffin etc. Gels are aqueous or alcoholic semisolid emulsion. Paste form of topical drugs are concentrated suspension of oil, water and powder. Aerosol or spray form of topical drug are solutions with pressurized propellant.

The OTC Topical drugs is segmented based on technology it utilizes such as Analgesics, Antibiotics, Antifungal, Antipruritic (Anti-Itch), Astringents and Others. Analgesics OTC topical drugs that are used for the pain relief. Antibiotic OTC topical drug inhibits the growth of microorganism and helps to killing them. Antifungal OTC topical drug treat and prevent fungicides and fungistatic and helps in treating and preventing mycoses. Antipruritic OTC topical drugs are also known as anti- itch drugs, these are medication that prevent the itching associated with reactions, eczema, sunburn, chickenpox etc.

The global market for OTC Topical drugs market is expected to be driven by the increasing number of patent cliff for topical drugs. The key drivers of the market are the increasing prevalence of skin diseases, allergic cases due to increasing pollution and other diseases. Moreover, the increasing incidence of skin cancer due to changing lifestyle, exposure to harmful carcinogens is also expected to act as the fuel to the growth of OTC Topical drugs market and is expected to drive the market within the forecast period of 2017-2027. However, use of other medication and the companies focus to introduce better innovative topical drug is expected to hinder the growth of OTC topical drug market.

The increasing awareness among population regarding the use of several OTC topical drugs is one of the major reason to drive the market. Based on the drug class OTC Topical drugs are divided based on the distribution channel such as hospital pharmacies, retail pharmacies, online pharmacies and drug stores.

By regional presence, OTC Topical drugs is segmented into five key regions viz. North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. North America will continue to dominate the OTC Topical drugs due to better healthcare facilities and increased cases of skin diseases. Europe and APAC is expected to hold large market share in global OTC Topical drugs. The increasing focus towards better healthcare system and the increasing geriatric population in APAC region is expected to grow the OTC Topical drugs market in this region.

Some of the major players in global OTC Topical drugs includes Novartis AG, GlaxoSmithKline plc. Sanofi, Merck & Co., Inc., Pfizer Inc., Bayer AG, Johnson & Johnson Private Limited, Abbott, Teva Pharmaceutical Industries Ltd, Hoffmann-La Roche Ltd and others.

About Persistence Market Research (PMR)

Persistence Market Research (persistencemarketresearch.com) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Persistence Market Research (P) Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Rahul Singh - PersistenceMarketResearch.com 
646-568-7751 sales[.]persistencemarketresearch.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Persistence Market Research (P) Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Persistence Market Research (P) Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)